scholarly journals Supramolecular caging for cytosolic delivery of anionic probes

2019 ◽  
Vol 10 (39) ◽  
pp. 8930-8938 ◽  
Author(s):  
Héctor Fernández-Caro ◽  
Irene Lostalé-Seijo ◽  
Miguel Martínez-Calvo ◽  
Jesús Mosquera ◽  
José L. Mascareñas ◽  
...  

A cell-permeable peptide-cage hybrid allows the cytosolic delivery of cage-interacting probes, including pyranine, carboxyfluorescein, and Alexa Fluor dyes, which are usually membrane-impermeable due to their high anionic charge.

2021 ◽  
Vol 7 (4) ◽  
pp. 641-649
Author(s):  
Susan L. Knox ◽  
Rebecca Wissner ◽  
Samantha Piszkiewicz ◽  
Alanna Schepartz

Theranostics ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. 3708-3721 ◽  
Author(s):  
Danhui Ma ◽  
Yutian Zou ◽  
Yunxiang Chu ◽  
Zhengsheng Liu ◽  
Gaochao Liu ◽  
...  

2002 ◽  
Vol 277 (51) ◽  
pp. 49989-49997 ◽  
Author(s):  
Gang Xu ◽  
Carlos Arregui ◽  
Jack Lilien ◽  
Janne Balsamo

The nonreceptor tyrosine phosphatase PTP1B associates with the cytoplasmic domain of N-cadherin and may regulate cadherin function through dephosphorylation of β-catenin. We have now identified the domain on N-cadherin to which PTP1B binds and characterized the effect of perturbing this domain on cadherin function. Deletion constructs lacking amino acids 872–891 fail to bind PTP1B. This domain partially overlaps with the β-catenin binding domain. To further define the relationship of these two sites, we used peptides to competein vitrobinding. A peptide representing the most NH2-terminal 8 amino acids of the PTP1B binding site, the region of overlap with the β-catenin target, effectively competes for binding of β-catenin but is much less effective in competing PTP1B, whereas two peptides representing the remaining 12 amino acids have no effect on β-catenin binding but effectively compete for PTP1B binding. Introduction into embryonic chick retina cells of a cell-permeable peptide mimicking the 8 most COOH-terminal amino acids in the PTP1B target domain, the region most distant from the β-catenin target site, prevents binding of PTP1B, increases the pool of free, tyrosine-phosphorylated β-catenin, and results in loss of N-cadherin function. N-cadherin lacking this same region of the PTP1B target site does not associate with PTP1B or β-catenin and is not efficiently expressed at the cell surface of transfected L cells. Thus, interaction of PTP1B with N-cadherin is essential for its association with β-catenin, stable expression at the cell surface, and consequently, cadherin function.


2007 ◽  
Vol 85 (12) ◽  
pp. 1405-1412 ◽  
Author(s):  
Gisela Tünnemann ◽  
Peter Karczewski ◽  
Hannelore Haase ◽  
M. Cristina Cardoso ◽  
Ingo Morano

Blood ◽  
2008 ◽  
Vol 112 (1) ◽  
pp. 56-63 ◽  
Author(s):  
Mariska G. Rondaij ◽  
Ruben Bierings ◽  
Ellen L. van Agtmaal ◽  
Karina A. Gijzen ◽  
Erica Sellink ◽  
...  

Abstract The small GTP-binding protein Ral has been implicated in regulated exocytosis via its interaction with the mammalian exocyst complex. We have previously demonstrated that Ral is involved in exocytosis of Weibel-Palade bodies (WPBs). Little is known about intracellular signaling pathways that promote activation of Ral in response to ligand binding of G protein–coupled receptors. Here we show that RNAi-mediated knockdown of RalGDS, an exchange factor for Ral, results in inhibition of thrombin- and epinephrine-induced exocytosis of WPBs, while overexpression of RalGDS promotes exocytosis of WPBs. A RalGDS variant lacking its exchange domain behaves in a dominant negative manner by blocking release of WPBs. We also provide evidence that RalGDS binds calmodulin (CaM) via an amino-terminal CaM-binding domain. RalGDS association to CaM is required for Ral activation because a cell-permeable peptide comprising this RalGDS CaM-binding domain inhibits Ral activation and WPB exocytosis. Together our findings suggest that RalGDS plays a vital role in the regulation of Ral-dependent WPB exocytosis after stimulation with Ca2+- or cAMP-raising agonists.


2011 ◽  
Vol 26 (11) ◽  
pp. 2031-2039 ◽  
Author(s):  
Deborah J. Stearns-Kurosawa ◽  
Valta Collins ◽  
Scott Freeman ◽  
Diann Debord ◽  
Kiyotaka Nishikawa ◽  
...  

Blood ◽  
2003 ◽  
Vol 102 (4) ◽  
pp. 1307-1315 ◽  
Author(s):  
Zhengyan Wang ◽  
Tina M. Leisner ◽  
Leslie V. Parise

Abstract The α2β1 integrin is a major collagen receptor on platelets. Although it has been proposed that α2β1, like αIIbβ3, undergoes agonist-induced activation, neither the potential contributions of α2β1 receptor/ligand internalization to the increase in ligand binding nor the roles of the α2 and β1 cytoplasmic domains in activation of this integrin have been previously explored. Activation of α2β1 was assessed with fluorescein isothiocyanate–labeled soluble type I collagen binding to platelets by flow cytometry. Although collagen internalization in response to agonist activation of platelets was significant, agonist-induced collagen binding still occurred under conditions that block internalization, with minimal changes in cell surface α2β1 expression. Introduction of cell-permeable peptides containing the α2 cytoplasmic tail, and especially the membrane proximal KLGFFKR domain, induced α2β1 activation in resting platelets, whereas a cell-permeable peptide containing the β1 cytoplasmic tail was without effect. Thus, collagen binding to stimulated platelets is increased due to α2β1 activation, in addition to internalization, and the GFFKR motif appears to play an important role in the activation process.


Biomolecules ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 1589
Author(s):  
Seong-Lan Yu ◽  
Han Koo ◽  
Se-In Lee ◽  
JaeKu Kang ◽  
Young-Hyun Han ◽  
...  

Homeobox A9 (HOXA9) expression is associated with the aggressive growth of cancer cells and poor prognosis in lung cancer. Previously, we showed that HOXA9 can serve as a potential therapeutic target for the treatment of metastatic non-small cell lung cancer (NSCLC). In the present study, we have carried out additional studies toward the development of a peptide-based therapeutic agent. Vectors expressing partial DNA fragments of HOXA9 were used to identify a unique domain involved in the inhibition of NSCLC cell invasion. Next, we performed in vitro invasion assays and examined the expression of EMT-related genes in transfected NSCLC cells. The C-terminal fragment (HOXA9-C) of HOXA9 inhibited cell invasion and led to upregulation of CDH1 and downregulation of SNAI2 in A549 and NCI-H1299 cells. Reduced SNAI2 expression was consistent with the decreased binding of transcription factor NF-kB to the SNAI2 promoter region in HOXA9-C overexpressing cells. Based on the above results, we synthesized a cell-permeable peptide, CPP33-HADP (HOXA9 active domain peptide), for lung-specific delivery and tested its therapeutic efficiency. CPP33-HADP effectively reduced the invasion ability of NSCLC cells in both in vitro and in vivo mouse models. Our results suggest that CPP33-HADP has significant potential for therapeutic applications in metastatic NSCLC.


BioTechniques ◽  
2020 ◽  
Vol 68 (4) ◽  
pp. 185-190 ◽  
Author(s):  
Liaqat Ali ◽  
Gauri Saxena ◽  
Meleri Jones ◽  
Georgia R Leisegang ◽  
Luke Gammon ◽  
...  

Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. Results: Alemtuzumab–Alexa Fluor 488 conjugate binding to the CHO-CD52 cell surface was inhibited by anti-alemtuzumab antibodies. Conclusion: In this proof-of-concept study, a CHO-CD52 cell line has been developed and used to detect the presence of anti-alemtuzumab neutralizing antibodies. This platform provides the basis of an assay for routine screening of serum for neutralizing antibodies from patients treated with alemtuzumab.


Sign in / Sign up

Export Citation Format

Share Document